Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Poolbeg Pharma is set to present promising pre-clinical data on its drug POLB 001, which appears to reduce Cytokine Release Syndrome (CRS) in animal models. This development could potentially ease the delivery of cancer immunotherapy treatments, opening up opportunities for broader access and safer administration. The findings will be shared at the prestigious American Society of Hematology Annual Meeting, drawing attention from investors interested in biopharmaceutical advancements.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.
